Amoxicillin/clavulanic acid pulsatile - MiddleBrook
Alternative Names: Amoxicillin/clavulanate pulsatile - GlaxoSmithKline/MiddleBrook; PULSYS amoxicillin/clavulanate combination; PULSYS amoxicillin/clavulanic acidLatest Information Update: 23 Dec 2021
At a glance
- Originator Advancis Pharmaceutical
- Developer MiddleBrook Pharmaceuticals
- Class 2 ring heterocyclic compounds; Antibacterials; Azetidines; Beta-lactams; Carboxylic acids; Oxazolidinones; Penicillins; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Sinusitis
Most Recent Events
- 26 Aug 2009 No development reported - Preclinical for Bacterial infections in USA (PO)
- 26 Aug 2009 No development reported - Preclinical for Sinusitis in USA (PO)
- 29 Jun 2007 Advancis Pharmaceutical is now called MiddleBrook Pharmaceuticals